These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 19808422)

  • 1. Should patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% undergo prophylactic implantation of an ICD? Patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% should undergo prophylactic implantation of an implantable cardioverter defibrillator.
    Silka MJ; Bar-Cohen Y
    Circ Arrhythm Electrophysiol; 2008 Oct; 1(4):298-306. PubMed ID: 19808422
    [No Abstract]   [Full Text] [Related]  

  • 2. Should patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% undergo prophylactic implantation of an ICD? Implantable cardioverter defibrillator implantation guidelines based solely on left ventricular ejection fraction do not apply to adults with congenital heart disease.
    Triedman JK
    Circ Arrhythm Electrophysiol; 2008 Oct; 1(4):307-16; discussion 316. PubMed ID: 19808423
    [No Abstract]   [Full Text] [Related]  

  • 3. Sudden cardiac death in adults with congenital heart disease.
    Yap SC; Harris L
    Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1605-20. PubMed ID: 19954322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Implantable cardioverter defibrillators in pediatric patients: results in a series of 33 cases].
    Tisserant A; Sadoul N; Kouakam C; Kacet S; Rey C; Chauvin M; Lévy J; Mabo P; Marçon F
    Arch Mal Coeur Vaiss; 2006 May; 99(5):433-8. PubMed ID: 16802731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost of preimplantation cardiac imaging in patients referred for a primary-prevention implantable cardioverter-defibrillator.
    Krahn AD; Hoch JS; Rockx MA; Leong-Sit P; Gula LJ; Yee R; Skanes AC; Klein GJ
    Am J Cardiol; 2008 Sep; 102(5):588-92. PubMed ID: 18721517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implantable cardioverter defibrillators and quality of life: results from the defibrillators in nonischemic cardiomyopathy treatment evaluation study.
    Passman R; Subacius H; Ruo B; Schaechter A; Howard A; Sears SF; Kadish A
    Arch Intern Med; 2007 Nov; 167(20):2226-32. PubMed ID: 17998496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can microvolt T-wave alternans testing reduce unnecessary defibrillator implantation?
    Armoundas AA; Hohnloser SH; Ikeda T; Cohen RJ
    Nat Clin Pract Cardiovasc Med; 2005 Oct; 2(10):522-8. PubMed ID: 16186850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sudden death prophylaxis in heart failure.
    Rosanio S; Schwarz ER; Vitarelli A; Zarraga IG; Kunapuli S; Ware DL; Birnbaum Y; Tuero E; Uretsky BF
    Int J Cardiol; 2007 Jul; 119(3):291-6. PubMed ID: 17208319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implantable cardioverter-defibrillators in children.
    Blom NA
    Pacing Clin Electrophysiol; 2008 Feb; 31 Suppl 1():S32-4. PubMed ID: 18226032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator?
    Al-Khatib SM; Han JY; Edwards R; Bardy GH; Bigger JT; Buxton AE; Cappato R; Dorian P; Hallstrom A; Kadish AH; Kudenchuk PJ; Lee KL; Mark DB; Moss AJ; Steinman R; Inoue LY; Sanders GD
    Int J Cardiol; 2014 Mar; 172(1):253-4. PubMed ID: 24467982
    [No Abstract]   [Full Text] [Related]  

  • 11. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
    Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
    Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risk stratification for sudden cardiac death: should we juist consider ejection fraction?].
    Paolucci M; Cattafi G; Magenta G; Vecchi MR; Schirru M; Lunati M
    G Ital Cardiol (Rome); 2008 Oct; 9(10 Suppl 1):27S-32S. PubMed ID: 19195303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of implantable cardioverter defibrillators in adults with congenital heart disease: a multi-centre study.
    Yap SC; Roos-Hesselink JW; Hoendermis ES; Budts W; Vliegen HW; Mulder BJ; van Dijk AP; Schalij MJ; Drenthen W
    Eur Heart J; 2007 Aug; 28(15):1854-61. PubMed ID: 17030523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A shock lead intentionally placed in the left ventricle.
    Kraaier K; Verhorst PM; Scholten MF
    Pacing Clin Electrophysiol; 2009 May; 32(5):675-6. PubMed ID: 19422593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defibrillator for primary prevention in congenital heart disease.
    Sueblinvong V; Ovadia M
    Pacing Clin Electrophysiol; 2004 Aug; 27(8):1167-9. PubMed ID: 15305972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary prevention of sudden cardiac death. do we need to implant a defibrillator in all the patients with low ejection fraction?
    Disertori M; El-Sherif N
    Ital Heart J; 2004 Sep; 5(9):643-7. PubMed ID: 15568590
    [No Abstract]   [Full Text] [Related]  

  • 17. Implant and clinical characteristics for pediatric and congenital heart patients in the national cardiovascular data registry implantable cardioverter defibrillator registry.
    Jordan CP; Freedenberg V; Wang Y; Curtis JP; Gleva MJ; Berul CI
    Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1092-100. PubMed ID: 25287482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population.
    Cowie MR; Marshall D; Drummond M; Ferko N; Maschio M; Ekman M; de Roy L; Heidbuchel H; Verboven Y; Braunschweig F; Linde C; Boriani G
    Europace; 2009 Jun; 11(6):716-26. PubMed ID: 19359333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons from a population: the limitations of left ventricular ejection fraction as the major determinant for primary prevention implantable cardioverter-defibrillators.
    Groh WJ
    J Am Coll Cardiol; 2006 Mar; 47(6):1167-8. PubMed ID: 16545647
    [No Abstract]   [Full Text] [Related]  

  • 20. Lesion-specific differences for implantable cardioverter defibrillator therapies in adults with congenital heart disease.
    Kella DK; Merchant FM; Veledar E; Book W; Lloyd MS
    Pacing Clin Electrophysiol; 2014 Nov; 37(11):1492-8. PubMed ID: 24889130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.